The Committee will seek to understand why certain areas have better access to clinical trials, more curative treatment options, and more advanced services than others. Questions are likely to be asked over why early diagnosis rates vary by as much as 16% between different areas. MPs are also likely to examine why survival rates are lower for more deprived socio-economic groups.
The Committee is also expected to consider how less survivable and less common cancers fit into the NHS’s long-term cancer plan. This includes how effectively the Government’s investment in new community diagnostic hubs will improve diagnosis of less common and less survivable cancers.